Systematic Review and Meta-Analysis to Estimate the Treatment Effect and Inform a Noninferiority Margin for a Phase 3 Noninferiority Trial in Uncomplicated Urogenital Gonorrhea. Issue 9 (8th September 2022)

• Record Type: Journal Article
• Authors: Mitrani-Gold, Fanny S.; Fix, Jonathan; Donald, Alison
• Is Part Of: Sexually transmitted diseases. Volume 49:Issue 9(2022)
• Page Start: 635
• Page End: 643
• Publication Date: 2022-09-08
• Subjects: Sexually transmitted diseases -- Periodicals; Sexual health -- Periodicals; 616.951005
• DOI: 10.1097/OLQ.0000000000001657
• Languages: English
• ISSNs: 0148-5717

Abstract

Abstract : A noninferiority margin of 15% preserved 65% of the ceftriaxone treatment effect, which could help inform the design, conduct, and analysis of future clinical studies in uncomplicated urogenital gonorrhea. Abstract : Background: Active-controlled noninferiority studies are used to investigate novel agents for uncomplicated urogenital gonorrhea (uUGC) as placebo-controlled trials are unethical. A systematic literature review and meta-analysis were conducted to estimate the ceftriaxone and proxy-for-placebo microbiological treatment effect and determine an appropriate noninferiority margin for phase 3 trials. Methods: Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines were followed. To account for interstudy variability, a weighted, noniterative random-effects model was fitted using "R" software to estimate the microbiological response rate and 95% confidence intervals (CIs) for ceftriaxone and proxy-for-placebo (treatment with an antibiotic the isolate was subsequently confirmed resistant to, or spontaneous resolution without treatment). I 2, τ 2, and P values were computed and included in the meta-analysis forest plot. Results: Seventeen studies were included in the meta-analysis; 14 reported ceftriaxone response in micro-intent-to-treat and microbiologically evaluable populations, and 3 reported proxy-for-placebo treatment response in uUGC (microbiologically evaluable population only). Microbiological treatment effect was estimated by subtracting the upper end of the CI for placebo from the lower end of the CI for ceftriaxone. Overall microbiological response was 98% (95% CI, 97–99) for ceftriaxone and 44% (95% CI, 34–54) for proxy-for-placebo, resulting in a microbiological treatment effect of 43%. A noninferiority margin of 15% preserved 65% of the ceftriaxone treatment effect, exceeding the 50% recommended per US Food and Drug Administration guidance for noninferiority studies. Conclusions: Results of this systematic literature review and meta-analysis could help inform the design, conduct, and analysis of future clinical studies in uUGC.